Lentinan injection

Pharmacological effects Lentinan is an anti-tumor auxiliary drug with immunomodulatory effects. It can promote the proliferation of T and B lymphocytes and increase the activity of NK cells. Animal experiments show that this product has a certain inhibitory effect on animal tumors (such as S-180 sarcoma and EC solid tumors). Toxicological studies Repeated dosing toxicity: Reticuloendothelial cell swelling and proliferation can be seen in rats, dogs and monkeys in repeated dosing tests. In rats (≥0.03 mg/kg, 1 month; ≥0.01 mg/kg, 3 months) and monkeys (≥2 mg/kg, 6 months), arteritis of small and medium arteries can be seen. In the ≥2 mg/kg group, some dogs and monkeys have gastrointestinal or bladder bleeding, rash and ulcers. The above lesions, except for arteritis in rats, are only seen in high-dose groups, and there is a recovery trend after drug withdrawal. Monkeys and dogs injected with large doses of this product can produce foam cells and vasculitis. The foam reaction indicates that excessive polysaccharides enter the tissue. Especially the reticuloendothelial system. Genetic toxicity: The mutagenicity test result of this product is negative. Reproductive toxicity: Female rats were given 1.0 mg/kg of Lentinan before pregnancy, and no abnormalities were observed. Male rats were given 0.01 mg/kg and no fertilization abnormalities were observed, but mild to moderate fertilization abnormalities were observed in the 0.1 and 1.0 mg/kg groups. In the experiments of administration during the organogenesis period of rats and rabbits, the maximum doses were 5.0 mg/kg and 1.0 mg/kg, respectively, and no teratogenic effects were observed, but the weight of the offspring was slightly lower after weaning. No abnormalities were observed when rats were given 5.0 mg/kg of Lentinan during the perinatal and lactation periods.

The main ingredient of this product is Lentinan, whose chemical name is szlig;-(1-3)(1-6)-D-glucose.

This product is a colorless, clear liquid.

It can replenish qi and strengthen spleen, tonify deficiency and strengthen body. It is used as an adjuvant for radiotherapy and chemotherapy of chronic persistent hepatitis B and digestive tract tumors.

For tumor immunotherapy, pleural and abdominal effusion is treated by intracavitary injection. 20 mg (5 vials) of Lentinan injection is injected into the pleural and abdominal cavity, 8 mg of Lentinan injection is injected into the pleural and abdominal cavity twice a week, and once a day by intramuscular injection.

1. Shock: It is relatively rare, so patients should be closely observed after taking the drug. If symptoms such as abnormal sensation in the mouth, chills, abnormal heart rhythm, decreased blood pressure, and difficulty breathing occur, the drug should be discontinued immediately and treated appropriately. 2. Skin: Rashes and redness may occur occasionally, and the drug should be discontinued. 3. Respiratory system: Chest pressure and throat constriction may occur occasionally, and they should be closely observed. If they occur, the administration rate should be slowed down, such as changing intravenous push to drip or slowing down the drip rate. 4. Digestive system: Nausea, vomiting, and loss of appetite may occur occasionally. 5. Nervous system: Headache, heavy head, and dizziness may occur occasionally. 6. Blood: Occasionally, red blood cells, white blood cells, and hemoglobin may decrease. 7. Others: Occasionally, fever, sweating, facial flushing, and other symptoms may occur.

Patients who are allergic to this product are prohibited from using it.

Precautions for children: Since there is no clinical experience with premature infants, newborns, infants and young children, its safety needs further study. Precautions for pregnancy and lactation: There is currently no clinical experience with the drug for pregnant and lactating women, and its safety needs further study.

This product should not be mixed with vitamin A preparations.

seal

2ml:1mg

18 months

Jinling Pharmaceutical Co., Ltd. Fuzhou Meifeng Pharmaceutical Factory

• Founded in:

  1998-11-02

• Address:

  No. 1, Jintang Road, Jinshan Development Zone, Fuzhou

• Tax NO.:

  913501001544221503

• Registered Funds:

  -

• Email:

  Log in to view